High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: Outcomes at 6 months and 1 year in the SYNERGY trial Academic Article uri icon

Overview

MeSH Major

  • Enoxaparin
  • Fibrinolytic Agents
  • Heparin
  • Myocardial Ischemia

abstract

  • In the SYNERGY trial, patients continued to experience adverse cardiac events through long-term follow-up. The effect of enoxaparin on death or MI compared with that of unfractionated heparin at 6 months was similar to that observed at 30 days in the overall trial and in the consistent-therapy group. One-year death rates were also similar in both groups. High-risk patients with ACS remain susceptible to continued cardiac events despite aggressive therapies.ClinicalTrials.gov Identifier: NCT00043784.

publication date

  • November 23, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1001/jama.294.20.2594

PubMed ID

  • 16304073

Additional Document Info

start page

  • 2594

end page

  • 600

volume

  • 294

number

  • 20